Applications of (S)-(-)-4-Benzyloxazolidine-2,5-Dione in Industrial Manufacturing

As a direct manufacturer, we supply (S)-(-)-4-Benzyloxazolidine-2,5-Dione for targeted downstream applications where chiral intermediates influence high-value synthesis, particularly across the pharmaceutical sector, advanced agrochemical process chains, and specialty chiral materials. Our production partners integrate this compound for its consistent stereoselectivity and reproducible batch-to-batch purity.

1. Chiral Intermediate for β-Lactam Antibiotic Synthesis

Our customers incorporate this chiral auxiliary in the asymmetric synthesis of β-lactam rings, a key structure in critical cephalosporin and carbapenem APIs. Chemical manufacturers use the oxazolidine-dione to direct enantioselective cyclization steps, meeting stringent impurity profiles and regulatory demands. The compound enters synthesis routes either via direct condensation with amino acid precursors or through ring-opening under controlled basic conditions, dictating product chirality and minimizing unwanted isomers. Downstream QC teams monitor integration points to ensure full conversion and recovery of auxiliary residues before active ingredient isolation.

Industry compliance standards

• ICH Q7 – GMP for Active Pharmaceutical Ingredients
• USP and EP monograph requirements for β-lactam APIs
• 21 CFR Part 210/211 for pharmaceutical processing in the USA
• EDQM CEP processes for manufacturer site approval

Typical usage ratio

• 10–20 mol% relative to key amino acid substrate; optimized for yield and ease of auxiliary removal based on pilot batch results

Downstream process integration

• Applied in the initial cyclization or condensation stage preceding API-forming steps; removed post-cyclization or recovered for reuse via chromatographic extraction or acid/base workup

Final product types

• Semi-synthetic cephalosporins (e.g., cefadroxil, cefcapene pivoxil)
• Carbapenem intermediate building blocks
• Bulk enantiopure β-lactam API intermediates

2. Resolution Agent in Enantiopure Amino Acid Production

Several large-scale peptide and pharmaceutical ingredient producers deploy this compound as a resolving agent to achieve high enantiopurity in cyclic and acyclic amino acids. The oxazolidine-2,5-dione forms diastereomers with racemic amino acids, allowing selective crystallization or chromatographic separation of the (S)- or (R)-enantiomers. Process engineers favor its high recovery and recyclability rates, as well as stability under both acidic and basic processing, enabling reliable throughput from lab to plant scale. Regulatory audits often check for the absence of auxiliary-derived by-products in isolated amino acids.

Industry compliance standards

• USP-NF General Chapters for amino acid purity (USP <461>, <621>)
• IFANCA and FSSC 22000 for food-grade amino acid facilities
• European Pharmacopoeia 2.2.31 enantiomeric purity testing
• ISO 9001:2015 for quality management systems

Typical usage ratio

• 30–35 mol% based on total amino acid input; adjusted based on the racemate:auxiliary solubility and diastereomer formation constants

Downstream process integration

• Added post-racemate salt formation, prior to chromatographic or fractional crystallization steps; fully cleaved and separated during product isolation

Final product types

• Enantiopure L- and D-amino acids for peptide synthesis
• Optically active intermediates for pharma and biotech
• Feedstock for chiral specialty chemicals

3. Precursor in Non-Proteinogenic Amino Acid Synthesis

Advanced chemical manufacturers rely on (S)-(-)-4-Benzyloxazolidine-2,5-Dione as a key precursor for constructing non-proteinogenic amino acids used in peptidomimetic drugs and enzyme inhibitor research. Integrators select it for ring opening modifications that introduce desired side chains while maintaining absolute configuration. Upstream operations employ precise stoichiometry and reaction control to avoid racemization, with repeated batch audits to document impurity clearance. The stability of protected intermediates supports flexible storage before downstream deprotection and functionalization steps.

Industry compliance standards

• ICH Q11 – Development and Manufacture of Drug Substances
• Chemical Manufacturers Association Responsible Care® initiatives
• REACH Annex IV exemptions for intermediates
• ISO 14001 environmental management (for specialty API intermediates)

Typical usage ratio

• 1:1 molar equivalent in coupling and derivatization protocols; excess may be used to offset minor losses from hydrolysis

Downstream process integration

• Supplied as a protected chiral building block at the initial coupling stage; reacts under mild, non-racemizing conditions, then subjected to deprotection after chain modification

Final product types

• Beta-hydroxy and N-alkylated non-natural amino acids
• Peptidomimetic core fragments for anti-infective candidates
• Advanced research intermediates for protease inhibitor development

4. Starting Material for Asymmetric Synthesis in Specialty Agrochemicals

Several large-scale agrochemical producers integrate this chiral building block as an entry point for manufacturing enantioselective herbicide, fungicide, or insecticide actives. Process scientists choose it in catalytic asymmetric syntheses to impart the required configuration in nitrogen-containing heterocycles, which often define the biological selectivity of finished agrochemicals. Production lines incorporate tailored purification and auxiliary cleavage protocols based on volume output, with compliance audits ensuring full auxiliary removal before formulation or export to blenders.

Industry compliance standards

• ISO 9001 and ISO 14001 management systems for agrochemical synthesis
• FAO/WHO specifications for pesticide active ingredients
• OECD Good Laboratory Practice (GLP) for residue analysis
• EU 1107/2009 Regulation on plant protection product approval

Typical usage ratio

• Ranges from 5 mol% for large-volume heterocycle formation to up to equimolar (1:1) in small-lot specialty routes; scaled per synthetic pathway and conversion efficiency

Downstream process integration

• Incorporated at the chirality induction stage of nitrogen heterocycle assembly, with final auxiliary cleavage before downstream formulation or crystallization of active ingredient

Final product types

• Selective herbicide precursors and intermediates
• Specialty chiral fungicide actives
• Intermediates for optically active insecticides